BioLineRX
BLRX
20 hedge funds and large institutions have $29.3M invested in BioLineRX in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
9% more capital invested
Capital invested by funds: $26.9M → $29.3M (+$2.35M)
20% less funds holding
Funds holding: 25 → 20 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$669K |
| 2 |
Morgan Stanley
New York
|
+$424K |
| 3 |
Millennium Management
New York
|
+$301K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$269K |
| 5 |
BCA
Benchmark Capital Advisors
New York
|
+$68.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.17M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.57M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$408K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$145K |
| 5 |
Jane Street
New York
|
-$39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KA
26
Kovack Advisors
Ft. Lauderdale,
Florida
| – | -$30K | -24 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$17K | -13 | Closed |
|
28
Citigroup
New York
| – | -$11K | -8 | Closed |
|
BLRX Hedge Fund Activity: Q2 2015 in Review
20 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2015, worth a combined $29.3M — up 8.7% from $26.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BLRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Senvest Management, adding an estimated $669K. The largest seller was BVF Inc, exiting entirely with an estimated $3.17M sold.
- 20 institutional investors held BioLineRX (BLRX) as of Q2 2015, down from 25 in Q1 2015.
- Funds reported $29.3M of BioLineRX stock for Q2 2015, up 8.7% quarter-over-quarter.
- 3 funds opened new BioLineRX positions in Q2 2015 and 8 closed out, a net change of -5 holders.
- The largest BioLineRX buyer in Q2 2015 was Senvest Management, an estimated $669K added.
- The largest BioLineRX seller in Q2 2015 was BVF Inc, an estimated $3.17M sold.
Based on aggregated 13F filings for Q2 2015.